|
1）Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995; 83: 835-9
|
|
|
|
2）Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001; 60: 14-30
|
|
|
|
|
|
3）Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest. 2000; 106: 1305-7
|
|
|
|
|
|
4）Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A. 1997; 94: 4312-7
|
|
|
|
|
|
5）Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004; 10: 355-61
|
|
|
|
|
|
6）Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol. 2007; 292: F1141-50
|
|
|
|
|
|
7）Okada T, Wada J, Hida K, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes. 2006; 55: 1666-77
|
|
|
|
|
|
8）Kawai T, Masaki T, Doi S, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest. 2009; 89: 47-58
|
|
|
|
|
|
9）Yang HC, Ma LJ, Ma J, et al. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int. 2006; 69: 1756-64
|
|
|
|
|
|
10）Endo Y, Suzuki M, Yamada H, et al. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARgamma-dependent nongenomic signaling. Cell Metab. 2011; 13: 550-61
|
|
|
|
|
|
11）Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996; 37: 907-25
|
|
|
|
|
|
12）Nagai T, Tomizawa T, Nakajima K, et al. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb. 2000; 7: 91-6
|
|
|
|
|
13）Sacks FM. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol. 2008; 102: 34l-40l
|
|
|
|
|
|
14）Park CW, Kim HW, Ko SH, et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes. 2006; 55: 885-93
|
|
|
|
|
|
15）Park CW, Zhang Y, Zhang X, et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 2006; 69: 1511-7
|
|
|
|
|
|
16）Zhou Y, Kong X, Zhao P, et al. Peroxisome proliferator-activated receptor-alpha is renoprotective in doxorubicin-induced glomerular injury. Kidney Int. 2011; 79: 1302-11
|
|
|
|
|
|
17）Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A. 2003; 100: 15924-9
|
|
|
|
|
|
18）Letavernier E, Perez J, Joye E, et al. Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol. 2005; 16: 2395-402
|
|
|
|
|
|
19）Matsushita Y, Ogawa D, Wada J, et al. Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes. 2011; 60: 960-8
|
|
|
|
|
|
20）Liang YJ, Chen SA, Jian JH. Peroxisome proliferator-activated receptor delta downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice. Eur J Pharm Sci. 2011; 43: 65-70
|
|
|
|
|
|
21）Wang Y, Borchert ML, Deluca HF. Identification of the vitamin D receptor in various cells of the mouse kidney. Kidney Int. 2012; 81: 993-1001
|
|
|
|
|
|
22）Wang XX, Jiang T, Shen Y, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011; 300: F801-10
|
|
|
|
|
|
23）Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2012; 302: F647-57
|
|
|
|
|
|
24）Zhang Y, Kong J, Deb DK, et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol. 2010; 21: 966-73
|
|
|
|
|
|
25）Deb DK, Wang Y, Zhang Z, et al. Molecular mechanism underlying 1,25-dihydroxyvitamin D regulation of nephrin gene expression. J Biol Chem. 2011; 286: 32011-7
|
|
|
|
|
|
26）Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis. 2009; 54: 647-52
|
|
|
|
|
|
27）Szeto CC, Chow KM, Kwan BC, et al. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis. 2008; 51: 724-31
|
|
|
|
|
|
28）Wolf M, Betancourt J, Chang Y, et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol. 2008; 19: 1379-88
|
|
|
|
|
|
29）de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010; 376: 1543-51
|
|
|
|
|